Appointment of Adviser

Ananda Developments PLC
06 February 2024
 

ANANDA DEVELOPMENTS PLC

 

("Ananda" or the "Company")

 

Ananda Appoints Data and Analytics Expert

 

Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Vitalii Ratushnyi as an adviser to the Company with a focus on data and analytics.

 

Vitalii is a data, analytics, and quantitative modelling expert. His appointment gives Ananda the analytical capability to better target its research activities by identifying potential current and new disease areas where cannabinoids may be efficacious. His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities. The Company's objective is to provide the evidence required to get cannabis-based medicines available on the NHS.

 

Ananda CEO Melissa Sturgess commented "We believe our ability to get to grips with large biological and genetic data sets will help us find opportunities for our cannabinoid medicines, guide the design of clinical trials and will be a cornerstone of our success. This work is critical for the rapid development of our clinical trials pipeline and intellectual property estate."

 

Biography

Vitalii holds a Master of Business Administration from the Kyiv University of Technology and Design, where he majored in Computer Science and minored in Behavioural Psychology. Vitalii has nine years of experience in the technology sector, beginning his career as a Data Engineer and Solution Architect for several Israeli companies. He has also been a foundational engineer in various start-ups, bringing his unique perspective and technical skills to the forefront of innovation. Vitalii currently works at an investment fund, where he creates quantitative models and tools to support investment decisions.

 

To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:  

  

·              Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·              LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·              Twitter: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For more information please contact:

InvestorHub

Engage with us directly at Ananda Developments Investor Hub

 

Sign up at https://investors.anandadevelopments.com/s/a66906

 

ANANDA DEVELOPMENTS PLC

Chief Executive Officer

Melissa Sturgess


Executive Director

Jeremy Sturgess-Smith

 

+44 (0)7463 686 497 ir@anandadevelopments.com

SP ANGEL CORPORATE FINANCE LLP

Corporate Finance

Richard Morrison

Harry Davies-Ball

+44 (0)20 3470 0470

Corporate Broking

Abigail Wayne

Rob Rees

 


Yellow Jersey PR

Charles Goodwin

Soraya Jackson

+44 (0)20 3004 9512

 

 

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based

medicines for the treatment of complex, chronic inflammatory pain conditions.

 

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

https://investors.anandadevelopments.com/link/Ky0KoP

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings